A carregar...
Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
INTRODUCTION: Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway. METHODS: We summarize the available phase...
Na minha lista:
| Publicado no: | Dermatol Ther (Heidelb) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Healthcare
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5574739/ https://ncbi.nlm.nih.gov/pubmed/28639011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-017-0187-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|